Stockhead on MSN
Alterity delivers encouraging phase II data in MSA trial
Alterity Therapeutics’ phase II study of its lead compound ATH434 in multiple system atrophy (MSA) has been featured in an ...
YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year 1 , and achieved record brand profitability ...
Q3 2025 Earnings Call Transcript November 10, 2025 Wave Life Sciences Ltd. misses on earnings expectations. Reported EPS is $ ...
The Hearty Soul on MSN
Nature's ‘Miracle Berry': How This Siberian Fruit Supports Health and Longevity
Have you ever heard of The Holy Fruit of the Himalayas? How about the Siberian Pineapple? Though it may come with a variety ...
Background Overuse of CT scans is associated with multiple harms, such as an increased risk of cancer development, particularly in children. However, the rate of CT scan use is high and unwarranted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback